articleScienceApr 22, 2020HYBRID OA

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

WDWenhao DaiBZBing ZhangXJXia-Ming JiangHSHaixia SuJLJian Li

China Pharmaceutical University · Chinese Academy of Sciences · +8 more institutions

PubMed
Indexed incrossrefdatacitepubmed

Abstract

Promising antiviral protease inhibitors With no vaccine or proven effective drug against the virus that causes coronavirus disease 2019 (COVID-19), scientists are racing to find clinical antiviral treatments. A promising drug target is the viral main protease M pro , which plays a key role in viral replication and transcription. Dai et al. designed two inhibitors, 11a and 11b, based on analyzing the structure of the M pro active site. Both strongly inhibited the activity of M pro and showed good antiviral activity in cell culture. Compound 11a had better pharmacokinetic properties and low toxicity when tested in mice and dogs, suggesting that this compound is a promising drug candidate. Science , this issue p.…

Citation impact

1,595
total citations
FWCI
33.87
Percentile
100%
References
29
Citations per year

Authors

27

Topics & keywords

Topics
Keywords
  • Coronavirus
  • Protease
  • Antiviral drug
  • In vivo
  • Chemistry
  • Virology
  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
  • Coronavirus disease 2019 (COVID-19)
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding